Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 22723290)

1.

The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.

Mathai SC, Puhan MA, Lam D, Wise RA.

Am J Respir Crit Care Med. 2012 Sep 1;186(5):428-33. doi: 10.1164/rccm.201203-0480OC. Epub 2012 Jun 21.

2.

Repeatability of the six-minute walk test and relation to physical function in survivors of a critical illness.

Alison JA, Kenny P, King MT, McKinley S, Aitken LM, Leslie GD, Elliott D.

Phys Ther. 2012 Dec;92(12):1556-63. doi: 10.2522/ptj.20110410. Epub 2012 May 10.

3.

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.

Chest. 2012 Dec;142(6):1383-90. doi: 10.1378/chest.11-2212.

PMID:
22628490
4.

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.

Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ; PHIRST Study Group.

J Am Coll Cardiol. 2012 Aug 21;60(8):768-74. doi: 10.1016/j.jacc.2012.05.004. Epub 2012 Jul 18.

5.

Sex differences in response to tadalafil in pulmonary arterial hypertension.

Mathai SC, Hassoun PM, Puhan MA, Zhou Y, Wise RA.

Chest. 2015 Jan;147(1):188-97. doi: 10.1378/chest.14-0263.

PMID:
25122150
6.

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.

Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ.

Circulation. 2013 Feb 5;127(5):624-33. doi: 10.1161/CIRCULATIONAHA.112.124388. Epub 2013 Jan 10.

7.

Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension.

Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M.

Curr Med Res Opin. 2009 Oct;25(10):2479-85. doi: 10.1185/03007990903210066.

PMID:
19686085
8.

Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil.

Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP.

Chest. 2009 Jan;135(1):137-42. doi: 10.1378/chest.07-0275. Epub 2008 Sep 23.

PMID:
18812447
9.

Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension.

Gomberg-Maitland M, Huo D, Benza RL, McLaughlin VV, Tapson VF, Barst RJ.

J Heart Lung Transplant. 2007 Jul;26(7):732-8. Epub 2007 Jun 13.

PMID:
17613405
10.

Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.

Udeoji DU, Schwarz ER.

Ther Adv Respir Dis. 2013 Feb;7(1):39-49. doi: 10.1177/1753465812463627. Epub 2012 Nov 5. Review.

PMID:
23129569
11.

Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.

Strange G, Keogh AM, Williams TJ, Wlodarczyk J, McNeil KD, Gabbay E.

Respirology. 2008 Sep;13(5):674-82. doi: 10.1111/j.1440-1843.2008.01326.x.

PMID:
18713089
12.

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.

Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK.

Thorax. 2010 Feb;65(2):173-7. doi: 10.1136/thx.2009.113498. Epub 2009 Dec 8.

13.

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N; STRIDE-2 Study Group.

J Am Coll Cardiol. 2006 May 16;47(10):2049-56. Epub 2006 Apr 24.

14.

A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.

Durongpisitkul K, Jakrapanichakul D, Sompradikul S.

J Med Assoc Thai. 2008 Feb;91(2):196-202.

PMID:
18389984
15.

Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7. doi: 10.1164/rccm.201007-1179OC. Epub 2010 Dec 3.

PMID:
21131468
16.

Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.

Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F.

Regul Pept. 2008 Nov 29;151(1-3):48-53. doi: 10.1016/j.regpep.2008.08.002. Epub 2008 Aug 16.

PMID:
18796317
17.

Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.

Arif SA, Poon H.

Clin Ther. 2011 Aug;33(8):993-1004. doi: 10.1016/j.clinthera.2011.06.008. Epub 2011 Jul 16. Review.

PMID:
21762988
18.

Quality of life as a prognostic marker in pulmonary arterial hypertension.

Fernandes CJ, Martins BC, Jardim CV, Ciconelli RM, Morinaga LK, Breda AP, Hoette S, Souza R.

Health Qual Life Outcomes. 2014 Aug 30;12:130. doi: 10.1186/s12955-014-0130-3.

19.

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.

Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group.

J Heart Lung Transplant. 2011 Jun;30(6):632-43. doi: 10.1016/j.healun.2010.11.009. Epub 2011 Jan 21.

PMID:
21256048
20.

Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.

Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ.

Ann Rheum Dis. 2007 Nov;66(11):1467-72. Epub 2007 May 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk